The 14-day studies can be run in parallel and not in series. So there is no need for it to take anything like 30 x 14 days.
It is intended that if the 14-day results satisfy efficacy and toxicity requirements then the trial will be expanded to evaluate RECCE 327 against current best treatment for wound infections. I would expect an update at least by that stage, and more likely well before that.
If past practice is any guide some pretty solid clues probably will arise at any time in videoed CEO interviews.
The 14-day studies can be run in parallel and not in series. So...
Add to My Watchlist
What is My Watchlist?
